Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Extrapolation: Experience gained from original biologics
Luisa Fernanda Rojas, Fernando de Mora
Drug Discovery Today (2021) Vol. 26, Iss. 8, pp. 2003-2013
Open Access | Times Cited: 12

Showing 12 citing articles:

Biosimilars: A Critical Review of Development, Regulatory Landscape, and Clinical Implications
Ankit Monga, Gagan, Pragya Jamwal, et al.
AAPS PharmSciTech (2025) Vol. 26, Iss. 1
Closed Access | Times Cited: 1
Expanding access to biotherapeutics in low-income and middle-income countries through public health non-exclusive voluntary intellectual property licensing: considerations, requirements, and opportunities
Sébastien Morin, Giulia Segafredo, Manuele Piccolis, et al.
The Lancet Global Health (2022) Vol. 11, Iss. 1, pp. e145-e154
Closed Access | Times Cited: 31
Switching from Biosimilar to Biosimilar Adalimumab, Including Multiple Switching, in Crohn’s Disease: A Prospective Study
Davide Giuseppe Ribaldone, Elisa Tribocco, Chiara Rosso, et al.
Journal of Clinical Medicine (2021) Vol. 10, Iss. 15, pp. 3387-3387
Open Access | Times Cited: 26
Biosimilars: Science, Implications, and Potential Outlooks in the Middle East and Africa
Radwa Ahmed Batran, Mai Elmoshneb, Ahmed Hussein, et al.
Biologics (2022) Vol. Volume 16, pp. 161-171
Open Access | Times Cited: 12
‘Totality of Evidence’ Approach in the Development of GP2017, an Approved Adalimumab Biosimilar
Norman Gaylis, Charlotte Both, Lena Lemke, et al.
Advances in Therapy (2024) Vol. 41, Iss. 5, pp. 1795-1814
Open Access | Times Cited: 1
The Role of PD Biomarkers in Biosimilar Development – To Get the Right Answer One Must First Ask the Right Question
Gillian R. Woollett, Joseph P. Park, Jihyun Han, et al.
Clinical Pharmacology & Therapeutics (2022) Vol. 113, Iss. 1, pp. 50-54
Open Access | Times Cited: 6
Overlapping biosimilar and originator follitropin alfa preparations: How much closer can they get?
Fernando de Mora, Colin M. Howles
Drug Discovery Today (2022) Vol. 27, Iss. 8, pp. 2071-2075
Open Access | Times Cited: 4
Resistant Chronic Spontaneous Urticaria – A Case Series Narrative Review of Treatment Options
Sujoy Khan, Charu Chopra, Alaistair Mitchell, et al.
Allergy & Rhinology (2022) Vol. 13
Open Access | Times Cited: 3
Post-approval quality-related regulatory actions for biopharmaceuticals approved in the European Union and the United States between 1995 and 2019
Ali M. Alsamil, Helga Gardarsdóttir, Hubert G. M. Leufkens, et al.
Drug Discovery Today (2023) Vol. 28, Iss. 10, pp. 103725-103725
Open Access | Times Cited: 1
Biosimilars: Principles, Regulatory Framework, and Societal Aspects
Arnold G. Vulto, Liese Barbier
Pharmaceutical biotechnology (2024), pp. 267-281
Closed Access
Nature and timing of post-approval manufacturing changes of tumour necrosis factor α inhibitor products: A 20-year follow-up study of originators and biosimilars
Ali M. Alsamil, Thijs J. Giezen, Toine C. G. Egberts, et al.
European Journal of Pharmaceutical Sciences (2022) Vol. 175, pp. 106227-106227
Open Access | Times Cited: 1
Quality of biopharmaceuticals: Comparability exercise and post-approval surveillance
Ali Mohammed Alsamil
(2022)
Open Access | Times Cited: 1
Page 1

Scroll to top